Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1642
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18182277 | ANTIBODIES AGAINST CDCP1 FOR THE TREATMENT AND DETECTION OF CANCER | Non-Final OA | The Regents of the University of California |
| 17792673 | AGENT FOR PREVENTION OR TREATMENT OF DIABETIC AUTONOMIC NEUROPATHY | Final Rejection | MITSUBISHI TANABE PHARMA CORPORATION |
| 18316739 | Antibody Constructs for CLDN18.2 and CD3 | Non-Final OA | AMGEN INC. |
| 17759382 | SELF-ASSEMBLING PRODRUGS AS IMMUNE BOOSTERS FOR CANCER IMMUNOTHERAPY | Final Rejection | THE JOHNS HOPKINS UNIVERSITY |
| 19011427 | TIL EXPANSION FROM FINE NEEDLE ASPIRATES AND SMALL BIOPSIES | Non-Final OA | Iovance Biotherapeutics, Inc. |
| 18185493 | ANG2-BINDING MOLECULES | Non-Final OA | Boehringer Ingelheim International GmBH |
| 18143749 | Use of Anti-EGFR/Anti-Met Antibody to Treat Liver Cancer | Non-Final OA | Janssen Biotech, Inc. |
| 18020436 | CELL SURFACE MICA AND MICB DETECTION USING ANTIBODIES | Non-Final OA | INNATE PHARMA |
| 18062871 | BINDING MOLECULES THAT MODULATE A BIOLOGICAL ACTIVITY EXPRESSED BY A CELL | Non-Final OA | Merus N.V. |
| 18315183 | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS | Non-Final OA | Immatics Biotechnologies GmbH |
| 17621815 | ANTI-CD33 ANTIBODIES FOR TREATING CANCER | Non-Final OA | MEMORIAL SLOAN KETTERING CANCER CENTER |
| 17536715 | TUMOR MUTATIONAL LOAD | Final Rejection | Memorial Sloan Kettering Cancer Center |
| 18125762 | REDUCING FRATRICIDE OF IMMUNE CELLS EXPRESSING NKG2D-BASED RECEPTORS | Non-Final OA | CELYAD S.A. |
| 18180116 | CD28 BISPECIFIC ANTIBODIES FOR TARGETED T CELL ACTIVATION | Non-Final OA | Novimmune SA |
| 17998841 | ABCG2 EFFLUX PUMP-CANCER ANTIGEN MULTI-SPECIFIC ANTIBODIES AND COMPOSITIONS, REAGENTS, KITS AND METHODS RELATED THERETO | Non-Final OA | William Robert Arathoon Living Trust Dated August 29, 2016 |
| 17910007 | ENGINEERED IMMUNE CELL EXPRESSING NK INHIBITORY MOLECULE AND USE THEREOF | Non-Final OA | NANJING BIOHENG BIOTECH CO., LTD |
| 17996743 | ANTI-CORONAVIRUS ANTIBODIES AND USES THEREOF | Non-Final OA | Ab Studio Inc. |
| 17739400 | COLON AND PANCREAS CANCER SPECIFIC ANTIGENS AND ANTIBODIES | Final Rejection | Precision Biologics, Inc. |
| 17524511 | ROR1 ANTIBODY IMMUNOCONJUGATES | Non-Final OA | VelosBio Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy